Skip to main content
SpringerLink
Log in

Intense P53 Staining is a Valuable Prognostic Indicator for Poor Prognosis in Medulloblastoma/central Nervous System Primitive Neuroectodermal Tumors

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Intense p53 immunostaining may predict for a poor prognosis in central nervous system primitive neuroectodermal tumor of childhood.

Background: Medulloblastoma is a common childhood primary brain tumor. Potential prognostic indicators for patients with local disease are age, extent of resection, and gender. However, none of these are well established. Immunohistologic staining is a potentially useful means to identify high-risk patients. The purpose of this clinical pathologic study was to investigate the prognostic significance of GFAP, synaptophysin, Ki-67, and p53 immunostaining in medulloblastoma/central nervous system primitive neuroectodermal tumors (CNS PNETs.)

Materials and methods: The records of 40 patients with CNS PNETs were reviewed. Their surgical specimens were immunostained for p53, glial fibrillary acidic protein (GFAP), synaptophysin, and Ki-67. The p53 specimens were scored blindly for the intensity of staining of nuclei (intense vs weak) and the quantity of cells stained. The Ki-67, GFAP, and synaptophysin specimens were analyzed for quantity of cells stained.

Results: Ten patients' specimens stained intensely for the p53 protein. Eleven had weakly staining nuclei. Nineteen specimens had no staining. The patients with specimens that stained intensely had a statistically significant decreased disease free survival (P = 0.03). Mere presence or quantity of p53 nuclear staining did not correlate with disease free survival. Immunohistochemical staining for Ki-67, GFAP, and synaptophysin did not correlate with disease free survival. Clinical parameters of age, gender, and extent of resection also did not approach statistical break significance for disease free survival.

Conclusion: Intense nuclear staining for p53 was the only variable in this clinical pathologic study that reached statistical significance for disease free survival. This suggests that intense staining for p53 may be the most important prognostic indicator for non-metastatic CNS PNETs. p53 Immunostaining with antibodies against p53 in CNS PNETs should be studied in a multi-institutional setting with larger numbers of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gurney JG, Davis S, Severson RK, Fang J, Ross JA, Robison LL: Trends in cancer incidence among children in the US. Cancer 78: 532–541, 1996

    Google Scholar 

  2. Evans AE, Jenkin DT, Sposto R, Ortega JA, Wilson CB, Wara W, Ertel IJ, Kramer S, Chang CH, Leikin SL, Hammond GD: The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72: 572–582, 1990

    Google Scholar 

  3. Tait DM, Thornton-Jones H, Bloom HJG, Lemerle J, Morris-Jones P: Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the international society of paediatric oncology (SIOP I). Europ J Cancer 26: 464–469, 1990

    Google Scholar 

  4. Krischer JP, Ragab AH, Kun L, Kim TH, Laurent JP, Boyett JM, Cornell CJ, Link M, Luthy AR, Camitta B: Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma: a Pediatric Oncology Group Study. J Neurosurg 74: 905–909, 1991

    Google Scholar 

  5. Packer RJ, Sutton NL, Angio G. Evans AE, Schut L: Management of children with primitive neuroectodermal tumors of the posterior fossa/medulloblastoma. Pediat Neurosci 12: 272–282, 1985-1986

    Google Scholar 

  6. Mulhern RK, Kepner JL, Thomas PR, Armstrong TF, Friedman HS, Kun LE: Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group Study. J Clin Oncol 16: 1723–1728, 1998

    Google Scholar 

  7. Merchant TE, Wang M, Haida T, Lindsley KL, Finlay J, Dunkel IJ, Rosenblum MK, Leibel SA: Medulloblastoma: long-term results for patients treated with definitive radiation therapy during the computed tomography era. Internat J Rad Oncol Biolog Phys 36: 29–35, 1996

    Google Scholar 

  8. Jin Y, Kayser S, Kemp BL, Ordonez NG, Tucker SL, Clayman GL, Goepfert H, Luna MA, Batsakis GJ, El-Naggar AK: The prognostic significance of the biomarkers p21 (WAF1/CIP1), p53, and bcl-2 in laryngeal sqamous cell carcinoma. Cancer 82: 2159–2165, 1998

    Google Scholar 

  9. Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda M, Bellot J, Abbor CC, Mazerolles C, Chopin DK: The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 80: 1472–1481, 1997

    Google Scholar 

  10. Miralbell R, Tolnay M, Bierl S: Pediatric medulloblasoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density. J Neuro-Oncol 45: 103–110, 1999

    Google Scholar 

  11. Jaros E, Lunec J, Perry RH, Kelly PJ, Pearson ADJ: p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. Br J Cancer 68: 801–807, 1993

    Google Scholar 

  12. Gerdes J, Lemke H, Baisch H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immun 133: 1710–1715, 1984

    Google Scholar 

  13. Hall PA, Levison DA, Woods AL: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285–294, 1990

    Google Scholar 

  14. Cattoretti G, Becker MHG, Key G: Monoclonal antibodies against recombinant parts of the KI-67 anigen (MIB1 and MIB3) detet proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357–363, 1992

    Google Scholar 

  15. Enestrom S, Vavruch L, Franlund B: Ki-67 antigen expression as a prognostic factor inprimary and recurrent astrocytomas. Neuro-Chirurgie 44: 25–30, 1998

    Google Scholar 

  16. Coffin CM, Braun JT, Wick MR: A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis of synaptophysin expression. Mod Pathol 3: 164–170, 1990

    Google Scholar 

  17. Herpers MJHM, Budka H: Primitive neuroectodermal tumors including the medulloblastoma: glial differentiation signaled by immunoreactivity for GFAP is restricted to the prue desmoplastic medulloblastoma ('arachnoidal sarcoma of the cerebellum'). Clin Neuropathol 4: 12–18, 1985

    Google Scholar 

  18. Kumanishi T, Washiyama K, Watabe K: Glial fibrillary acidic protein in medulloblastoma. Acta Neuropathologica 67: 1–5, 1985

    Google Scholar 

  19. Maraziotis T, Perentes E, Karamitopoulow E, Nakagawa Y: Neuron-associated class III beta-tubulin isotype, retinal S-antigen, synaptophysin, and glial fibrillary acidic protein in human medulloblastomas: a clinicopathologic analysis of 37 cases. Acta Neuropathologica 84: 355–363, 1992

    Google Scholar 

  20. Goldberg-Stern H, Gadoth N, Stern S: The prognostic significance of glial fibrillary acidic protein staining in medulloblastoma. Cancer 68: 568–573, 1991

    Google Scholar 

  21. Packer RJ, Sutton LN, Rorke LB, Littman PA: Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 61: 296–301, 1984

    Google Scholar 

  22. Batra SK, McLendon RE, Koo JS, Castelino-Prabhu S, Fuchs HE, Krischer JP, Friedman HS, Bigner DD, Bigner SH: Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neuro-Oncol 24: 39–45, 1995

    Google Scholar 

  23. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J: Molecular analyses of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16: 2478–2485, 1998

    Google Scholar 

  24. Zerbini C, Gelber RD, Weinberg D, Sallan SE, Barnes P, Kupsky W, Scott MR, Tarbell NJ: Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol 11: 616–622, 1993

    Google Scholar 

  25. Levine AJ, Momand J, Finlay C: The p53 tumor suppressor gene. Nature 351: 453–465, 1991

    Google Scholar 

  26. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923–935, 1992

    Google Scholar 

  27. Finley CA, Hinds PW, Levine AJ: The p53 Proto-oncogene can act as a suppressor of transformation. Cell 57: 1083–1093, 1989

    Google Scholar 

  28. Sabbatini P, Lin J, Levine AJ, White E: Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes and Development 9: 2184–2192, 1995

    Google Scholar 

  29. Reich NC, Oren M, Levine AJ: Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cellular Biol 3(12): 2143–2150, 1983

    Google Scholar 

  30. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, Levine AJ: Mutant p53 DNA clones from human colon carcinomas cooperated with ras in transforming primary rat cells: a comparison of the ‘hot spot’ mutant phenotypes. Cell Growth Differentiation 1: 571–580, 1990

    Google Scholar 

  31. Ambros RA, Ross JS, Kallakury BVS, Malfetano J, Kim Y, Hwang J, Breese K, Figge J: p53 gene satus in endometial carcinoma showing diffuse positivity for p53 protein by immunohistochemial analysis. Mod Pathol 8: 441–445, 1995

    Google Scholar 

  32. Ono Y, Tamiya T, Ichikawa T, Matsumoto K, Furuta T, Ohmoto T, Akiyama K, Seki S, Ueki K, Louis DN: Accumulation of wild-type p53 in astrocytoms is associated with increased p21 expression. Acta Neuropathol 94: 21–27, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, USA

    Robert T. Woodburn & Joseph F. Montebello

  2. Department of Neuropathology, Indiana University Medical Center, Indianapolis, IN, USA

    Biagio Azzarelli & Iva E. Goss

Authors
  1. Robert T. Woodburn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Biagio Azzarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph F. Montebello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Iva E. Goss
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Woodburn, R.T., Azzarelli, B., Montebello, J.F. et al. Intense P53 Staining is a Valuable Prognostic Indicator for Poor Prognosis in Medulloblastoma/central Nervous System Primitive Neuroectodermal Tumors. J Neurooncol 52, 57–62 (2001). https://doi.org/10.1023/A:1010691330670

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010691330670

Search

Navigation